Naratriptan Dosing and Contraindications
The recommended adult dose of naratriptan is 1 mg or 2.5 mg orally, with the option to repeat once after 4 hours if needed, not exceeding 5 mg in 24 hours. 1
Standard Dosing
- Initial dose: 1 mg or 2.5 mg orally
- Repeat dosing: May repeat once after 4 hours if migraine returns or partial response occurs
- Maximum daily dose: 5 mg per 24-hour period
- Treatment frequency: Safety beyond treating 4 migraine attacks per 30-day period has not been established 1
The 2.5 mg dose offers the optimal efficacy-to-tolerability ratio, with adverse event rates similar to placebo 1. Current guidelines position naratriptan as one of several triptan options for acute migraine treatment, with selection based on individual patient factors including route preference and cost 2.
Dose Adjustments
Renal Impairment
- Mild to moderate impairment: Start with 1 mg; maximum 2.5 mg per 24 hours
- Severe impairment (CrCl <15 mL/min): Contraindicated 1
Hepatic Impairment
- Child-Pugh Grade A or B: Start with 1 mg; maximum 2.5 mg per 24 hours
- Child-Pugh Grade C: Contraindicated 1
Geriatric Patients
Start at the low end of dosing range (1 mg) due to higher likelihood of decreased renal/hepatic function and increased cardiovascular risk. Cardiovascular evaluation recommended before initiating therapy in elderly patients with cardiovascular risk factors 1.
Absolute Contraindications
Cardiovascular:
- Ischemic coronary artery disease (angina, prior MI, documented silent ischemia)
- Coronary artery vasospasm, including Prinzmetal's angina
- Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders
- History of stroke or transient ischemic attack
- Hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension 1
Drug Interactions:
- Recent use (within 24 hours) of another 5-HT₁ agonist (triptan)
- Recent use (within 24 hours) of ergotamine-containing or ergot-type medications (dihydroergotamine, methysergide) 1
Other:
- Hypersensitivity to naratriptan (angioedema and anaphylaxis reported)
- Severe renal impairment (CrCl <15 mL/min)
- Severe hepatic impairment (Child-Pugh Grade C) 1
Clinical Context
Guideline positioning: The 2025 American College of Physicians guideline recommends adding a triptan to an NSAID (or acetaminophen if NSAIDs contraindicated) when adequate doses of NSAID/acetaminophen alone provide insufficient relief 2. Naratriptan is listed among seven acceptable triptans, with selection based on patient-specific factors.
Pediatric use: Not recommended for patients <18 years; efficacy not established in adolescents 1.
Pregnancy/lactation: Not addressed in current guidelines for acute migraine; no data on presence in human milk. Risk-benefit assessment required 1.
Key pitfall: Cardiovascular evaluation is essential before prescribing to patients with multiple cardiovascular risk factors, even without known coronary disease, as serious cardiac events including acute MI have been reported 1.